HCPCS code J3245: Tildrakizumab (Ilumya) billing guide

Key Takeaways

HCPCS code J3245 describes injection of tildrakizumab (Ilumya), 1 mg per unit, used to bill the biologic treatment for moderate-to-severe plaque psoriasis in adults

A standard 100 mg Ilumya dose requires 100 units of J3245 on the claim; incorrect unit counts are the leading cause of denials for this code

Medicare Part B reimburses J3245 at ASP+6% in non-facility settings; rates change quarterly and must be verified against the current CMS ASP pricing file

Pabau’s claims management software tracks HCPCS injection codes, links them to treatment records, and supports the audit documentation required for high-cost biologic claims

HCPCS code J3245 is the Level II Healthcare Common Procedure Coding System code assigned to the injection of tildrakizumab, 1 mg. The Centers for Medicare and Medicaid Services (CMS) maintains this code within the J-series of injectable drug codes, which cover drugs administered by injection that are not self-administered by the patient.

Tildrakizumab is marketed under the brand name Ilumya by Sun Pharmaceutical Industries and carries the USAN suffix tildrakizumab-asmn, which designates the biologic qualifier assigned by the FDA.

Ilumya is an interleukin-23 (IL-23) inhibitor approved by the FDA for treatment of moderate-to-severe plaque psoriasis in adults. The code is billable under Medicare Part B as a physician-administered drug. Per the CMS HCPCS overview, J-series codes apply to drugs that cannot be self-administered and are furnished incident to a physician’s professional service.

Tildrakizumab dosing and billing units for J3245

The unit convention for HCPCS code J3245 is 1 mg per unit. Because Ilumya is supplied and administered as a 100 mg subcutaneous injection, a single dose requires 100 units of J3245 on the claim. Billing fewer than 100 units for a standard dose is one of the most common errors that triggers a J3245 underpayment or denial.

The prescribing information confirmed via FDA labeling specifies the following dosing schedule for moderate-to-severe plaque psoriasis in adults.

Each claim for a standard Ilumya administration should show J3245 with units = 100. Practices using claims management software that links injection billing to treatment records can auto-populate the correct unit count from the documented dose, reducing manual entry errors on high-cost biologics.

Medicare reimbursement for HCPCS code J3245

Medicare Part B covers J3245 as a physician-administered drug under the ASP (Average Sales Price) payment methodology. CMS reimburses Part B drugs at ASP+6% in non-facility settings (office, outpatient clinic) and at ASP+6% in facility outpatient settings, though the provider portion of facility payments is subject to cost-sharing rules. Because ASP pricing is updated quarterly by CMS, do not rely on published third-party figures for claim submission. Always verify the current ASP file at the CMS Physician Fee Schedule lookup before billing a new quarter’s claims.

Commercial and managed Medicaid payers typically set their own contracted rates for J3245, which may differ substantially from Medicare ASP. For practices billing multiple payer types, tracking per-payer reimbursement rates against the documented dose and units helps identify underpayment patterns early. Connecting J3245 billing to revenue cycle management workflows gives practices an audit trail that supports both payer audits and internal contract reviews.

NDC to HCPCS J3245 crosswalk

Many payers, including Medicare, require the National Drug Code (NDC) to be reported on claims alongside HCPCS code J3245. The NDC identifies the specific drug product, package size, and labeler, providing a crosswalk from the pharmacy dispensing record to the HCPCS billing code. Tildrakizumab products are manufactured by Sun Pharmaceutical Industries and carry NDC codes that must be mapped to J3245 on the CMS-1500 or 837P claim.

Report NDC in the following format on the claim: qualifier N4 + 11-digit NDC (no dashes) + unit qualifier UN (units) + quantity dispensed. The specific NDC codes for tildrakizumab-asmn are subject to change when new lot configurations are released. Always confirm current NDCs against your wholesaler invoice or the AAPC HCPCS code reference rather than relying on a static list.

• NDC qualifier: N4 (reported in box 24A of the CMS-1500 or the 2400 loop of the 837P)
• NDC format: 11-digit number with no hyphens or spaces
• Unit qualifier: UN (unit)
• Quantity: number of milligrams dispensed (100 for a standard Ilumya dose)
• Source: wholesaler invoice or payer-specific NDC crosswalk tool

Practices that use electronic medical billing workflows can link the NDC from the dispensed drug record directly to the J3245 claim line, reducing transcription errors that cause NDC-related rejections. For practices exploring clearinghouse submission, Pabau integrates with Claim.MD, supporting 837P electronic claim submission and NDC reporting across 4,000+ US payers.

ICD-10 diagnosis codes required with HCPCS code J3245

Medical necessity for J3245 claims depends on pairing the HCPCS code with an appropriate ICD-10-CM diagnosis code. Payers use local coverage determinations (LCDs) and national coverage determinations (NCDs) to define which diagnoses support coverage for tildrakizumab. The diagnosis codes below reflect those commonly cited in payer LCDs for Ilumya; verify against your MAC’s specific LCD before submitting, since covered diagnoses vary by payer.

For dermatology practices billing J3245 frequently, linking ICD-10 codes to the structured treatment record in dermatology EMR software ensures the diagnosis documented at the visit matches what appears on the claim. A mismatch between the clinical note and the submitted ICD-10 code is a common trigger for payer audits on high-cost biologics. The CMS ICD-10 codes page provides official annual code updates and guidelines applicable to Medicare claims.

Prior authorization requirements for J3245

Commercial payers and managed Medicaid plans almost universally require prior authorization (PA) before they will reimburse J3245. Medicare does not require PA for most Part B drugs administered in a physician’s office, but managed Medicare (Medicare Advantage) plans may impose their own PA requirements. Never assume PA is waived based on the patient’s plan type alone; confirm with the specific payer before the first administration.

Common PA requirements across major payers for tildrakizumab include the following.

• Moderate-to-severe severity documentation: body surface area (BSA) involvement typically 10% or greater, or PASI/DLQI score thresholds specified by the payer
• Step therapy failure: most plans require documented inadequate response or contraindication to conventional systemic agents (methotrexate, cyclosporine, acitretin) before approving a biologic
• Prescriber specialty: some payers limit Ilumya PA approval to dermatology or rheumatology specialists
• Renewal PA: maintenance doses every 12 weeks often require annual PA renewal with documentation of ongoing treatment response
• Buy-and-bill vs specialty pharmacy: payer policy determines whether the drug is dispensed through a specialty pharmacy or obtained buy-and-bill; this affects both the claim type and the PA pathway

Missing or expired PA is the single largest denial driver for biologic injection codes. Practices managing multiple biologic patients benefit from tracking PA expiration dates alongside treatment schedules. Integrating this into HIPAA-compliant medical office workflows creates a documented trail of PA status at each administration date, which supports appeals when a payer retroactively disputes coverage.

Manage biologic billing and prior auth in one place

Pabau connects injection billing records, treatment documentation, and claims workflows so your team spends less time chasing denials and more time on patient care.

Book a demo

Billing guidelines and place of service for HCPCS code J3245

Correct place of service (POS) coding is essential for J3245 claims because the payer’s reimbursement rate varies by setting. An office administration billed with POS 22 (outpatient hospital) will trigger a rate reduction or denial because the facility fee is expected to cover the drug cost in that setting.

When submitting electronically, route through a clearinghouse that validates HCPCS codes, unit counts, and NDC fields before the claim reaches the payer. Pabau’s integration with medical claims clearinghouse partners supports real-time eligibility checks and 837P submission, helping flag unit-count and NDC errors before they become denials. For practices exploring electronic remittance workflows, the electronic remittance advice (ERA) process translates payer 835 files into actionable payment and denial data.

Common billing errors and denial prevention for J3245

J3245 generates a predictable set of claim denials, most of which are preventable with the right pre-submission checks. The errors below reflect the failure points that most frequently appear in biologic injection billing workflows, based on published payer denial patterns for J-series injectable drug codes.

• Wrong unit count: billing 1 unit instead of 100 for a 100 mg dose is the most common error; some practice management systems default to 1 unit for J-codes unless configured for mg-based dosing. Pre-submission audits that cross-reference the documented dose against the claimed units catch this before submission.
• Missing or mismatched ICD-10 code: submitting L40.9 (unspecified psoriasis) when the clinical note documents moderate-to-severe L40.0 plaque psoriasis invites medical necessity review. Code to the highest specificity the documentation supports.
• Prior authorization not obtained or expired: commercial and Medicare Advantage payers deny J3245 when PA is absent or lapsed. Track PA approval dates and expiration relative to each scheduled maintenance injection.
• NDC missing or incorrectly formatted: Medicare and many commercial payers require NDC on the claim. Missing N4 qualifier, dashes in the NDC, or reporting the NDC without quantity/unit qualifier results in automated rejection.
• Wrong place of service code: office administration billed as POS 22 reduces the reimbursement or triggers a facility-crossover denial. Confirm the actual setting at each encounter.
• Missing administration code: J3245 covers the drug only, not the injection service. Always bill the corresponding CPT administration code (typically 96372 for subcutaneous injection) on the same claim.

Practices managing recurring biologic patients benefit from a pre-authorization tracking log tied to each patient’s treatment schedule. Connecting denial management workflows to the billing system ensures that denied J3245 claims are flagged for appeal with the correct supporting documentation rather than written off. For a structured approach to clean claim submission, see the clean claim checklist, which covers the elements required across payer types for physician-administered drug billing.

J3245 related HCPCS and drug codes

Dermatology and rheumatology billing teams often code multiple IL-23, IL-17, and IL-12/23 inhibitors within the same patient panel. Understanding how J3245 relates to other biologic injection codes reduces miscoding risk when a patient switches therapies or when a practice bills several agents in the same claim cycle.

For a broader reference on HCPCS Level II code structure and how J-codes fit within the coding hierarchy, the PGM Billing HCPCS lookup tool provides a free searchable database based on CMS data. For practices managing multiple biologic agents, superbill workflows that tie each drug code to the administered treatment record help prevent cross-code billing errors at month-end.

Conclusion

The most preventable J3245 denials share a common root: a disconnect between what the clinical record documents and what the claim actually says. Wrong units, mismatched ICD-10 codes, lapsed PA, and missing NDC fields are each fixable at the workflow level before a claim ever leaves the practice.

Pabau’s claims management software links injection billing records directly to treatment documentation, so the unit count, diagnosis code, and administration date on the claim match what was documented at the visit. For dermatology and aesthetics practices administering high-cost biologics, that connection reduces denial rates and shortens the time between administration and reimbursement. To see how Pabau handles biologic billing workflows, book a demo.

Continue your research

Need to understand how clearinghouse submission works for J-codes? Medical claims clearinghouse guide explains how 837P electronic claims are validated and routed to payers before payment.

Want to reduce denials across all your HCPCS codes? Denial management in healthcare covers the end-to-end process for identifying, appealing, and preventing claim denials.

Looking for the billing compliance checklist for your practice? Medical billing compliance outlines the documentation and submission standards that protect practices during payer audits.

Frequently Asked Questions